Q-omics provides the consensus-scored TTYH3 profile across patient tissues and cancer cell-line models. TTYH3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TTYH3 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, TTYH3 protein abundance shows 21,900 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, HNSC, and BRCA as cancer lineages where TTYH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTYH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTYH3 survival associations across molecular data types. TTYH3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTYH3 RNA expression–survival associations across cancer types. High TTYH3 expression shows unfavorable associations in UVM, SKCM, MESO, LIHC and LGG, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TTYH3 RNA expression.
This table summarizes TTYH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TTYH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTYH3 shows higher tumor expression in HNSC, KIRC, COAD, BLCA, STAD and LIHC. The HNSC box plot shows higher TTYH3 RNA expression in tumor versus normal tissue (log2 FC = +2.863, t-test p < 0.001).
This table shows molecular features associated with TTYH3 in patient tissues and cancer cell lines. In patient samples, TTYH3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TTYH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
